Prostate Cancer Clinical Trial
Official title:
Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as
cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor
may not need treatment until it progresses. In this case, observation may be sufficient. It
is not yet known whether giving cyproterone acetate continuously is more effective than
giving cyproterone acetate after tumor progression in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying cyproterone acetate to compare how well
it works when given continuously or after tumor progression in treating patients with newly
diagnosed stage III or stage IV prostate cancer.
OBJECTIVES:
Primary
- Compare time to loss of androgen dependence, based on serum prostate-specific antigen
failure, in patients with newly diagnosed stage III or IV prostate cancer treated with
intermittent vs continuous androgen suppression comprising cyproterone acetate.
- Compare time to treatment failure (subjective or objective progression) in patients
treated with these regimens.
- Compare quality of life of patients treated with these regimens.
- Compare survival of patients treated with these regimens.
Secondary
- Compare the side effects in patients treated with these regimens.
- Determine the first and total therapy-free intervals in patients treated with
intermittent cyproterone acetate.
OUTLINE: This is a randomized, multicenter study.
All patients receive cyproterone acetate daily for 16 weeks. Patients also receive monthly
injections of luteinizing hormone-releasing hormone (LHRH) agonist beginning in week 2 and
continuing for 14 weeks. Patients with a prostate-specific antigen (PSA) level of ≤ 4 ng/mL
and who are asymptomatic at 14 weeks are randomized to 1 of 2 treatment arms.
- Arm I (continuous maximum-androgen blockade): Patients receive cyproterone acetate
daily and monthly LHRH agonist depot injections in the absence of disease progression
or unacceptable toxicity. Patients may also undergo orchidectomy.
Quality of life is assessed every 6 months for 2 years and then annually thereafter.
- Arm II (intermittent treatment): Patients are observed after randomization. Treatment
with daily cyproterone acetate resumes if symptoms demand hormone treatment and patient
has any PSA level OR if patient is asymptomatic and has a PSA level ≥ 20 ng/mL.
Treatment continues in the absence of disease progression or unacceptable toxicity. If
after 9 months of treatment, a PSA level of ≤ 4 ng/mL is not achieved or the patient
remains symptomatic, treatment is discontinued.
Quality of life is assessed every 6 months and when therapy is restarted.
Pain and performance status are assessed at each visit in both treatment arms.
After completion of study therapy, patients are followed periodically.
PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study.
;
Allocation: Randomized, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |